MX2020014120A - Agonistas parciales del receptor de insulina. - Google Patents

Agonistas parciales del receptor de insulina.

Info

Publication number
MX2020014120A
MX2020014120A MX2020014120A MX2020014120A MX2020014120A MX 2020014120 A MX2020014120 A MX 2020014120A MX 2020014120 A MX2020014120 A MX 2020014120A MX 2020014120 A MX2020014120 A MX 2020014120A MX 2020014120 A MX2020014120 A MX 2020014120A
Authority
MX
Mexico
Prior art keywords
partial agonists
insulin receptor
receptor partial
insulin
dimers
Prior art date
Application number
MX2020014120A
Other languages
English (en)
Inventor
Songnian Lin
Yuping Zhu
Pei Huo
Christina B Madsen-Duggan
zhi-cai Wu
Yingjun Mu
Ravi Nargund
Lin Yan
Dmitri Pissarnitski
Danqing Feng
Ahmet Kekec
Zhi- Cai Shi
Original Assignee
Merck Sharp & Dohme Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Llc filed Critical Merck Sharp & Dohme Llc
Publication of MX2020014120A publication Critical patent/MX2020014120A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se divulgan dímeros de insulina y dímeros de análogo de insulina que actúan como agonistas parciales en el receptor de insulina.
MX2020014120A 2014-11-21 2017-05-19 Agonistas parciales del receptor de insulina. MX2020014120A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462082857P 2014-11-21 2014-11-21
US201562242503P 2015-10-16 2015-10-16

Publications (1)

Publication Number Publication Date
MX2020014120A true MX2020014120A (es) 2021-03-25

Family

ID=54838417

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2017006651A MX2017006651A (es) 2014-11-21 2015-11-19 Agonistas parciales del receptor de insulina.
MX2020014121A MX2020014121A (es) 2014-11-21 2017-05-19 Agonistas parciales del receptor de insulina.
MX2020014120A MX2020014120A (es) 2014-11-21 2017-05-19 Agonistas parciales del receptor de insulina.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2017006651A MX2017006651A (es) 2014-11-21 2015-11-19 Agonistas parciales del receptor de insulina.
MX2020014121A MX2020014121A (es) 2014-11-21 2017-05-19 Agonistas parciales del receptor de insulina.

Country Status (27)

Country Link
US (4) US20170355743A1 (es)
EP (4) EP3666792A3 (es)
JP (5) JP6484337B2 (es)
KR (2) KR102101136B1 (es)
CN (2) CN112494656B (es)
AR (1) AR102712A1 (es)
AU (3) AU2015349890B2 (es)
BR (2) BR122024000898A2 (es)
CA (2) CA3014641C (es)
CL (3) CL2017001288A1 (es)
CO (1) CO2017004976A2 (es)
CR (1) CR20170208A (es)
DO (1) DOP2017000124A (es)
EA (1) EA036714B1 (es)
ES (1) ES2946247T3 (es)
GT (1) GT201700104A (es)
IL (1) IL252257A0 (es)
MX (3) MX2017006651A (es)
NI (1) NI201700060A (es)
PE (1) PE20170957A1 (es)
PH (1) PH12017500935A1 (es)
SG (4) SG11201704064TA (es)
SV (1) SV2017005445A (es)
TN (1) TN2017000178A1 (es)
TW (1) TW201625673A (es)
WO (1) WO2016081670A2 (es)
ZA (1) ZA201703238B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ766530A (en) 2014-08-04 2023-09-29 Nuevolution As Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
EP3666792A3 (en) 2014-11-21 2020-07-29 Merck Sharp & Dohme Corp. Insulin receptor partial agonists
AR105616A1 (es) 2015-05-07 2017-10-25 Lilly Co Eli Proteínas de fusión
US10953076B2 (en) 2016-05-24 2021-03-23 Merck Sharp & Dohme Corp. Insulin receptor partial agonists and GLP-1 analogues
EP3463413A4 (en) * 2016-05-25 2020-03-04 Merck Sharp & Dohme Corp. PARTIAL INSULIN RECEPTOR AGONISTS
MA46568A (fr) * 2016-10-24 2019-08-28 Novo Nordisk As Dosage biologique de formulations d'insuline
PE20211264A1 (es) 2017-08-17 2021-07-15 Novo Nordisk As Analogos de insulina acilados novedosos y usos de estos
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11911484B2 (en) 2018-08-02 2024-02-27 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US20220193250A1 (en) 2018-08-02 2022-06-23 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
JP2021532831A (ja) 2018-08-02 2021-12-02 ダイン セラピューティクス, インコーポレーテッドDyne Therapeutics, Inc. ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
CN112898172B (zh) * 2019-12-04 2022-05-31 中国科学院大连化学物理研究所 可被羧肽酶酶解的双亲和功能团化合物的合成方法
US11447479B2 (en) 2019-12-20 2022-09-20 Nuevolution A/S Compounds active towards nuclear receptors
WO2021198955A1 (en) 2020-03-31 2021-10-07 Nuevolution A/S Compounds active towards nuclear receptors
CA3174176A1 (en) 2020-03-31 2021-10-07 Sanne Schroder Glad Compounds active towards nuclear receptors
WO2022046747A1 (en) * 2020-08-26 2022-03-03 Merck Sharp & Dohme Corp. Insulin receptor partial agonists
JP2023540746A (ja) * 2020-09-03 2023-09-26 ダイン セラピューティクス，インコーポレーテッド タンパク質－オリゴヌクレオチド複合体の調製方法
EP4210729A2 (en) * 2020-09-09 2023-07-19 Merck Sharp & Dohme LLC Insulin receptor partial agonists
US11633498B2 (en) 2021-07-09 2023-04-25 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US11672872B2 (en) 2021-07-09 2023-06-13 Dyne Therapeutics, Inc. Anti-transferrin receptor antibody and uses thereof
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
US11931421B2 (en) 2022-04-15 2024-03-19 Dyne Therapeutics, Inc. Muscle targeting complexes and formulations for treating myotonic dystrophy

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1381273A (en) * 1971-01-28 1975-01-22 Nat Res Dev Insulin derivatives
US3907763A (en) 1972-03-01 1975-09-23 Bayer Ag Insulin derivatives crosslinked by a dicarboxylic acid moiety
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
US5514646A (en) 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
US5304473A (en) 1991-06-11 1994-04-19 Eli Lilly And Company A-C-B proinsulin, method of manufacturing and using same, and intermediates in insulin production
AU1272295A (en) 1993-12-17 1995-07-03 Novo Nordisk A/S Proinsulin-like compounds
AU5724996A (en) 1995-05-05 1996-11-21 Eli Lilly And Company Single chain insulin with high bioactivity
JP2002517437A (ja) 1998-06-08 2002-06-18 アドバンスド メディスン インコーポレーテッド 新規なナトリウムチャンネル薬剤および使用
DE19908041A1 (de) 1999-02-24 2000-08-31 Hoecker Hartwig Kovalent verbrückte Insulindimere
KR100449454B1 (ko) 2000-10-02 2004-09-21 이현철 단일사슬 인슐린 유도체의 유전자를 포함하는 당뇨병치료용 벡터
WO2002067969A2 (en) 2001-02-21 2002-09-06 Medtronic Minimed, Inc. Stabilized insulin formulations
US7105314B2 (en) 2001-04-02 2006-09-12 Novo Nordisk A/S Method for making human insulin precursors
DK1507769T4 (en) 2002-05-30 2018-01-02 Scripps Research Inst Copper-catalyzed ligation of azides and acetylenes
KR100507796B1 (ko) 2003-04-03 2005-08-17 한미약품 주식회사 생체내 반감기가 증가된 ｐｅｇ-생리활성 폴리펩티드 동종이량체 결합체 및 이의 제조방법
CN102816228A (zh) 2003-12-03 2012-12-12 诺和诺德公司 单链胰岛素
US20090197800A1 (en) 2004-10-27 2009-08-06 Novo Nordisk A/S Insulin Receptor Binding Peptides with Non-Insulin Gene Activation Profiles and Uses Thereof
PT1812031E (pt) 2004-11-01 2015-10-01 Univ California Composições e métodos para modificação de biomoléculas
JP2008533100A (ja) 2005-03-18 2008-08-21 ノボ ノルディスク アクティーゼルスカブ Ｐｅｇ化された単鎖インスリン
WO2007096332A1 (en) 2006-02-21 2007-08-30 Novo Nordisk A/S Single-chain insulin analogues and pharmaceutical formulations thereof
WO2007104738A2 (en) 2006-03-13 2007-09-20 Novo Nordisk A/S Acylated single chain insulin
WO2007104736A2 (en) 2006-03-13 2007-09-20 Novo Nordisk A/S Acylated single chain insulin
WO2007104734A1 (en) 2006-03-13 2007-09-20 Novo Nordisk A/S Acylated single chain insulin
US20090069215A1 (en) 2006-03-13 2009-03-12 Novo Nordisk A/S Acylated Single Chain Insulin
US9505823B2 (en) 2006-08-07 2016-11-29 TEV A Biopharmaceuticals USA, Inc. Albumin-insulin fusion proteins
WO2008145721A2 (en) * 2007-06-01 2008-12-04 Novo Nordisk A/S N-terminal modification of polypeptides for protection against degradation by aminopeptidases
JP2011511778A (ja) 2008-01-30 2011-04-14 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション エステルに基づいたペプチドプロドラッグ
WO2009132129A2 (en) 2008-04-22 2009-10-29 Case Western Reserve University Isoform-specific insulin analogues
TWI394580B (zh) 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
LT2349324T (lt) * 2008-10-17 2017-12-27 Sanofi-Aventis Deutschland Gmbh Insulino ir glp-1 agonisto derinys
US8481485B2 (en) 2008-12-19 2013-07-09 Indiana University Research And Technology Corporation Insulin analogs
CA2744558A1 (en) 2008-12-19 2010-07-15 Indiana University Research And Technology Corporation Amide-based insulin prodrugs
WO2011059895A1 (en) 2009-11-11 2011-05-19 Quest Diagnostics Investments Incorporated Hexa mutations
CN103068842B (zh) * 2010-06-16 2016-10-19 印第安纳大学研究及科技有限公司 对胰岛素受体具有高活性的单链胰岛素激动剂
US8255297B2 (en) 2010-07-20 2012-08-28 Facebook, Inc. Creation, redemption, and accounting in a virtual currency system
CN103154024A (zh) 2010-10-15 2013-06-12 诺沃—诺迪斯克有限公司 新型n末端修饰的胰岛素衍生物
BR112014010139A2 (pt) * 2011-10-27 2017-04-25 Univ Case Western Reserve formulação farmacêutica, método de redução do nível de açúcar no sangue de um paciente e polipeptídeo
US9593156B2 (en) 2012-09-26 2017-03-14 Indiana University Research And Technology Corporation Insulin analog dimers
CA2904198A1 (en) 2013-03-15 2014-09-18 Universite De Geneve Use of insulin signaling antagonists, optionally in combination of transfection of non-beta cells, for inducing insulin production
CA2924743A1 (en) * 2013-10-04 2015-04-09 Merck Sharp & Dohme Corp. Glucose-responsive insulin conjugates
US10758636B2 (en) * 2013-11-12 2020-09-01 Centre For Probe Development And Commercialization Residualizing linkers and uses thereof
MA46146A1 (fr) 2014-01-20 2020-12-31 Hanmi Pharm Ind Co Ltd Insuline a action prolongée et utilisation associée
EP3666792A3 (en) * 2014-11-21 2020-07-29 Merck Sharp & Dohme Corp. Insulin receptor partial agonists

Also Published As

Publication number Publication date
EP3660040A2 (en) 2020-06-03
SG11201704064TA (en) 2017-06-29
CL2019001143A1 (es) 2019-07-19
CN112494656A (zh) 2021-03-16
AU2018211208B2 (en) 2020-09-10
NI201700060A (es) 2017-07-18
KR20190069622A (ko) 2019-06-19
AU2018211207B2 (en) 2020-04-09
AU2015349890A1 (en) 2017-06-01
EA201791117A1 (ru) 2017-11-30
BR122024000898A2 (pt) 2024-02-27
PH12017500935A1 (en) 2017-11-27
JP2020097572A (ja) 2020-06-25
JP6931033B2 (ja) 2021-09-01
TW201625673A (zh) 2016-07-16
MX2020014121A (es) 2021-03-25
US10800827B2 (en) 2020-10-13
KR20170084300A (ko) 2017-07-19
WO2016081670A2 (en) 2016-05-26
CO2017004976A2 (es) 2017-10-10
BR112017010481A2 (pt) 2018-04-03
CA3014641A1 (en) 2016-05-26
EP3221343A2 (en) 2017-09-27
US10017556B2 (en) 2018-07-10
BR122024000903A2 (pt) 2024-02-27
JP6484337B2 (ja) 2019-03-13
US10183981B2 (en) 2019-01-22
CL2017001288A1 (es) 2017-12-15
EP3666792A3 (en) 2020-07-29
KR102101136B1 (ko) 2020-04-14
KR102049647B1 (ko) 2019-11-29
DOP2017000124A (es) 2017-08-15
CR20170208A (es) 2017-07-17
EP3221343B1 (en) 2020-09-16
CN108064173B (zh) 2021-05-18
AU2015349890B2 (en) 2018-08-30
CN108064173A (zh) 2018-05-22
US20190092833A1 (en) 2019-03-28
EP3660041B1 (en) 2023-04-19
MX2017006651A (es) 2017-08-21
JP2018501203A (ja) 2018-01-18
EP3660040A3 (en) 2020-07-29
CA2966765C (en) 2020-04-14
JP6943825B2 (ja) 2021-10-06
PE20170957A1 (es) 2017-07-13
AR102712A1 (es) 2017-03-22
CA3014641C (en) 2020-08-18
JP2019011357A (ja) 2019-01-24
US20170107268A1 (en) 2017-04-20
EA036714B1 (ru) 2020-12-10
WO2016081670A3 (en) 2016-08-04
CA2966765A1 (en) 2016-05-26
GT201700104A (es) 2018-11-27
JP2019014734A (ja) 2019-01-31
CL2019001144A1 (es) 2019-07-19
JP6703068B2 (ja) 2020-06-03
SV2017005445A (es) 2018-04-04
TN2017000178A1 (en) 2018-10-19
JP2019014735A (ja) 2019-01-31
AU2018211208A1 (en) 2018-08-16
IL252257A0 (en) 2017-07-31
ZA201703238B (en) 2018-05-30
SG10201809428UA (en) 2018-11-29
SG10201809457YA (en) 2018-11-29
CN112494656B (zh) 2024-01-30
EP3666792A2 (en) 2020-06-17
BR112017010481A8 (pt) 2023-04-11
US20180291078A1 (en) 2018-10-11
ES2946247T3 (es) 2023-07-14
EP3660041A1 (en) 2020-06-03
US20170355743A1 (en) 2017-12-14
AU2018211207A1 (en) 2018-08-16
SG10201809427SA (en) 2018-11-29

Similar Documents

Publication Publication Date Title
MX2020014120A (es) Agonistas parciales del receptor de insulina.
PH12016502142B1 (en) Anti-ptk7 antibody-drug conjugates
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
IN2015DE00625A (es)
SI3220893T1 (sl) Sestavek na osnovi COQ10
EP3045751A4 (en) OSCILLATING SKATE BEARING
LT3169322T (lt) Dietinė kompozicija su atidislipideminiu aktyvumu
NZ719451A (en) Glucagon analog for treatment of severe hypoglycemia
PL3279327T3 (pl) Nowy promotor i jego zastosowanie
EA201991576A1 (ru) Частичные агонисты инсулинового рецептора
UA99992U (ru) 2-оксо-4-фенил-5-циано-1,2,3,4-тетрагидропиридин-6-тиолат n-метилморфолиния
AP00748S1 (en) Desks
AU358556S (en) Strap fastener
GB201501738D0 (en) S.o.s.i.c.h.
IN2014CH00927A (es)
GB201417023D0 (en) Bizyfy.com
IN2014MU03184A (es)
GB201412127D0 (en) The cigarillo
GB201416411D0 (en) Trenchcover with retainer
GB201413121D0 (en) The E.M.S As Pripulsian
GB201403059D0 (en) The S.E.G
GB201400885D0 (en) MagneticChess.com
GB201400595D0 (en) The E.M.S as propotsion